Zobrazeno 1 - 10
of 313
pro vyhledávání: '"M. Bhavnani"'
Autor:
John P O’Donnell, Sujata M Bhavnani
Publikováno v:
Clinical Infectious Diseases. 76:S202-S209
Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5aada36c46a741c418b67981cc341d71
https://doi.org/10.1093/cid/ciad096
https://doi.org/10.1093/cid/ciad096
Publikováno v:
Antimicrobial Agents and Chemotherapy.
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral (PO) carbapenem pro-drug that is converted to the active moiety tebipenem in the enterocytes. Tebipenem has activity against multidrug-resistant Gram-negative pathogens, including extended-spectr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee3d59d79db35045766797da940bf9f9
https://doi.org/10.1128/aac.01451-22
https://doi.org/10.1128/aac.01451-22
Autor:
M. Trang, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e770f144165854688a9d0e098510f41
https://doi.org/10.1128/aac.02397-21
https://doi.org/10.1128/aac.02397-21
Autor:
Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f512cb865e5b1e50a1aff17b6dce35ce
https://doi.org/10.1128/aac.02213-21
https://doi.org/10.1128/aac.02213-21
Autor:
B. D. VanScoy, S. Jones, H. Conde, L. V. Friedrich, N. Cotroneo, S. M. Bhavnani, P. G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy.
Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections. Herein, we describe the results of studies designed to evaluate tebipenem’s potential as an oral (p.o.) transitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4738368fe1e9a6ab1e01362a7eaca378
https://doi.org/10.1128/aac.00908-22
https://doi.org/10.1128/aac.00908-22
Autor:
M. Trang, J. P. Hammel, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino
Publikováno v:
Antimicrobial agents and chemotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3673c99d808c84236c671280981e9ea3
https://pubmed.ncbi.nlm.nih.gov/36533934
https://pubmed.ncbi.nlm.nih.gov/36533934
Autor:
Sujata M Bhavnani, Jeffrey P Hammel, Harish Ganesan, M Courtney Safir, Christopher M Rubino, Paul G Ambrose, Kevin M Krause
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentrates in alveolar macrophages and exhibits potent activity against nontuberculous mycobacteria. PK-PD target attainment (PTA) analyse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec4ae4681fb8931d6361ed1197b8457
https://doi.org/10.1093/ofid/ofac492.671
https://doi.org/10.1093/ofid/ofac492.671
Publikováno v:
Open Forum Infectious Diseases. 9
Background Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which have higher predisposition to develop antifungal resistance (e.g., fks mutations conferring reduced susceptibility to echinocandins)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26ea862b210f436fd207863ebf479d72
https://doi.org/10.1093/ofid/ofac492.644
https://doi.org/10.1093/ofid/ofac492.644
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria, is under clinical development for treatment of MAC lung disease. A population pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e74c35815ec9a7cbf08300b3a77e9adc
https://doi.org/10.1093/ofid/ofac492.645
https://doi.org/10.1093/ofid/ofac492.645
Autor:
Sujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, Anthony P Cammarata, Kajal Larson, Kathryn Liolios, Sarah McLeod, Alita Miller, Paul G Ambrose, Ruben Tommasi, John O'Donnell
Publikováno v:
Open Forum Infectious Diseases. 9
Background SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, which are often severe and associated with substantial mortality. PPK, PTA, and clinical PK/PD analyses were conducted using all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4d2a3d650c63780862254dacfb13767
https://doi.org/10.1093/ofid/ofac492.1896
https://doi.org/10.1093/ofid/ofac492.1896